# Efficacy & Safety of TD-1473 in Ulcerative Colitis

> **NCT03758443** · PHASE2,PHASE3 · TERMINATED · sponsor: **Theravance Biopharma** · enrollment: 239 (actual)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** TD-1473 Dose A
- **DRUG:** TD-1473 Dose B
- **DRUG:** TD-1473 Dose C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03758443
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-11
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-10-20
- **Target enrollment:** 239 (ACTUAL)
- **Why stopped:** Stopped early due to company decision. Company decision based on interim analysis results in TD-1473-0157.
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758443, "Efficacy & Safety of TD-1473 in Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03758443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*